Clinical trial
A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.
NCT00281528 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.
- Lead sponsor
- Celgene
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 1, 2006
- Completion date
- March 1, 2011
- Enrollment
- 208 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.